Sustained immunogenicity of the HPV-16/18 AS04-adjuvanted vaccine administered as a two-dose schedule in adolescent girls: Five-year clinical data and modeling predictions from a randomized study

In this randomized, partially-blind study (clinicaltrials.gov; NCT00541970), the licensed formulation of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine (20 μg each of HPV-16/18 antigens) was found highly immunogenic up to 4 y after first vaccination, whether administered as a 2-dose (2...

Disgrifiad llawn

Wedi'i Gadw mewn:
Manylion Llyfryddiaeth
Cyhoeddwyd yn:Hum Vaccin Immunother
Prif Awduron: Romanowski, Barbara, Schwarz, Tino F, Ferguson, Linda, Peters, Klaus, Dionne, Marc, Behre, Ulrich, Schulze, Karin, Hillemanns, Peter, Suryakiran, Pemmaraju, Thomas, Florence, Struyf, Frank
Fformat: Artigo
Iaith:Inglês
Cyhoeddwyd: Taylor & Francis 2015
Pynciau:
Research Papers
Mynediad Ar-lein:https://ncbi.nlm.nih.gov/pmc/articles/PMC4962738/
https://ncbi.nlm.nih.gov/pubmed/26176261
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/21645515.2015.1065363
Tagiau: Ychwanegu Tag
Dim Tagiau, Byddwch y cyntaf i dagio'r cofnod hwn!

Eitemau Tebyg